Clinical trials: Extensive Stage Lung Small Cell Carcinoma
Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only)
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer…
- Conditions
- Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer
- Trial name
- EASE (NCT07636200)
- Testing
- Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Colorado, Boulder
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell…
- Trial name
- NCT05680922
- Testing
- LB2102
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Legend Biotech USA Inc
Lung Cancer
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
In this study, all patients must have already completed first-line chemotherapy to treat extensive-stage disease small cell lung cancer.
- Trial name
- CheckMate 451 (NCT02538666)
- Testing
- Nivolumab, Ipilimumab
- Where
- 197 sites in United States, Argentina and 30 more
- Volunteers
- 907 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Small Cell Lung
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting.
- Trial name
- NCT00294931
- Testing
- irinotecan, carboplatin, bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is a single arm, multi-center, open label phase Ib/II study of SC0245 and Irinotecan combination therapy in subjects with extensive-stage small cell lung cancer (ES-SCLC) as a second therapy.
- Trial name
- NCT05731518
- Testing
- SC0245, Irinotecan
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have…
- Trial name
- NCT05765825
- Testing
- serplulimab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 61 people
- Sponsor
- Sichuan University
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital